{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:27:57Z","timestamp":1789082877619,"version":"build-2803163510"},"reference-count":55,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Migraine is a neurovascular paroxysmal disorder characterized by neurogenic inflammation and has a remarkable impact on the quality of life. The Food and Drug Administration (FDA) approved onabotulinumtoxin A in 2010 for the prophylactic treatment of chronic migraine. Today, in its 4th decade, it is approved in 100 countries for 15 main indications. Its mechanism of action, based on the inhibition of neurotransmitter release from primary sensory neurons, is very complex: it affords antinociception, but it also has an analgesic effect on neuropathic pain conditions and reduces the need for rescue medications. Genetic variants have been investigated for their potential role in the pathogenesis and clinical expression of migraine and of the response to treatments. These studies primarily involved genes associated with vascular regulation and cardiovascular pathology, including those encoding angiotensin-converting enzyme (ACE) and methylenetetrahydrofolate reductase (MTHFR). However, epigenetics and, particularly, genetic and epigenetic modifications are still poorly studied in terms of understanding the mechanisms implicated in susceptibility to migraine, aura, chronification and response to symptomatic and preventive treatments. In particular, the aim of the present study is to gather evidence on the genetic variants and epigenetic modifications affecting the pathway of the calcitonin gene-related peptide (CGRP), the target of onabotulinumtoxin A and of all the novel monoclonal antibodies.<\/jats:p>","DOI":"10.3390\/toxins17070355","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T11:25:17Z","timestamp":1752751517000},"page":"355","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Translational Impact of Genetics and Epigenetics of CGRP System on Chronic Migraine Treatment with Onabotulinumtoxin A and Other Biotech Drugs"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5846-7058","authenticated-orcid":false,"given":"Damiana","family":"Scuteri","sequence":"first","affiliation":[{"name":"Department of Health Sciences, University \u201cMagna Graecia\u201d of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-4128","authenticated-orcid":false,"given":"Paolo","family":"Martelletti","sequence":"additional","affiliation":[{"name":"School of Health, Unitelma Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s10194-024-01889-x","article-title":"Hallmarks of primary headache: Part 1\u2014Migraine","volume":"25","author":"Raggi","year":"2024","journal-title":"J. Headache Pain"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s10194-018-0846-2","article-title":"Migraine is first cause of disability in under 50s: Will health politicians now take notice?","volume":"19","author":"Steiner","year":"2018","journal-title":"J. Headache Pain"},{"key":"ref_3","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018). The International Classification of Headache Disorders, International Headache Society. [3rd ed.]."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1212\/01.wnl.0000225186.76323.69","article-title":"Age-dependent prevalence and clinical features of migraine","volume":"67","author":"Bigal","year":"2006","journal-title":"Neurology"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Corasaniti, M.T., Lawrence, G.W., Bagetta, G., Iannacchero, R., Tarsitano, A., Monteleone, A., Pagliaro, M., Tonin, P., Sandrini, G., and Nicotera, P. (2023). Combination of anti-CGRP\/CGRP-R mAbs with onabotulinumtoxin A as a novel therapeutic approach for refractory chronic migraine: A retrospective study of real-world clinical evidence and a protocol for a double-blind, randomized clinical trial to establish the efficacy and safety. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1296577"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Scuteri, D., Tonin, P., Nicotera, P., Vulnera, M., Altieri, G.C., Tarsitano, A., Bagetta, G., and Corasaniti, M.T. (2022). Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine. Toxins, 14.","DOI":"10.3390\/toxins14080529"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1474-4422(06)70348-9","article-title":"Chronic disorders with episodic manifestations: Focus on epilepsy and migraine","volume":"5","author":"Haut","year":"2006","journal-title":"Lancet Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0140-6736(18)30478-1","article-title":"Migraine","volume":"391","author":"Dodick","year":"2018","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1212\/01.wnl.0000325565.63526.d2","article-title":"Clinical course in migraine: Conceptualizing migraine transformation","volume":"71","author":"Bigal","year":"2008","journal-title":"Neurology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0304-3959(03)00293-8","article-title":"Factors associated with the onset and remission of chronic daily headache in a population-based study","volume":"106","author":"Scher","year":"2003","journal-title":"Pain"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Zobdeh, F., Eremenko, I.I., Akan, M.A., Tarasov, V.V., Chubarev, V.N., Schi\u00f6th, H.B., and Mwinyi, J. (2023). The Epigenetics of Migraine. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119127"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s10194-017-0744-z","article-title":"Botulinum neurotoxin type A for the treatment of pain: Not just in migraine and trigeminal neuralgia","volume":"18","author":"Sandrini","year":"2017","journal-title":"J. Headache Pain"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"De Icco, R., Perrotta, A., Berra, E., Allena, M., Alfonsi, E., Tamburin, S., Serrao, M., Sandrini, G., and Tassorelli, C. (2019). OnabotulinumtoxinA Reduces Temporal Pain Processing at Spinal Level in Patients with Lower Limb Spasticity. Toxins, 11.","DOI":"10.3390\/toxins11060359"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1523\/JNEUROSCI.5490-08.2009","article-title":"Activation of TRPV1 Mediates Calcitonin Gene-Related Peptide Release, Which Excites Trigeminal Sensory Neurons and Is Attenuated by a Retargeted Botulinum Toxin with Anti-Nociceptive Potential","volume":"29","author":"Jianghui","year":"2009","journal-title":"J. Neurosci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0041-0101(99)00153-1","article-title":"Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins","volume":"38","author":"Welch","year":"2000","journal-title":"Toxicon"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache","volume":"86","author":"David","year":"2016","journal-title":"Neurology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","article-title":"OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results from the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program","volume":"50","author":"Dodick","year":"2010","journal-title":"Headache J. Head. Face Pain"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial","volume":"30","author":"Aurora","year":"2010","journal-title":"Cephalalgia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial","volume":"30","author":"Diener","year":"2010","journal-title":"Cephalalgia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s10194-019-1009-9","article-title":"Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs)","volume":"20","author":"Martelletti","year":"2019","journal-title":"J. Headache Pain"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s10194-019-1066-0","article-title":"Mechanisms of migraine as a chronic evolutive condition","volume":"20","author":"Andreou","year":"2019","journal-title":"J. Headache Pain"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1101\/gad.1787609","article-title":"An operational definition of epigenetics","volume":"23","author":"Berger","year":"2009","journal-title":"Genes Dev."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Meng, S., Zhou, H., Feng, Z., Xu, Z., Tang, Y., and Wu, M. (2019). Epigenetics in Neurodevelopment: Emerging Role of Circular RNA. Front. Cell. Neurosci., 13.","DOI":"10.3389\/fncel.2019.00327"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41392-023-01537-x","article-title":"TET (Ten-eleven translocation) family proteins: Structure, biological functions and applications","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s10194-024-01908-x","article-title":"Serum microRNA qPCR profiling and validation indicate upregulation of circulating miR-145-5p and miR-26a-5p in migraineurs","volume":"25","author":"Kordacka","year":"2024","journal-title":"J. Headache Pain"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"698","DOI":"10.2174\/1871527321666220426103253","article-title":"Common microRNAs in Epilepsy and Migraine: Their Possibility as Candidates for Biomarkers and Therapeutic Targets during Comorbid Onset of Both Conditions","volume":"22","author":"Ludhiadch","year":"2023","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s10194-024-01842-y","article-title":"Expression of miR-155 in monocytes of people with migraine: Association with phenotype, disease severity and inflammatory profile","volume":"25","author":"Greco","year":"2024","journal-title":"J. Headache Pain"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s10194-024-01800-8","article-title":"Altered immunity in migraine: A comprehensive scoping review","volume":"25","author":"Ha","year":"2024","journal-title":"J. Headache Pain"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s10194-023-01542-z","article-title":"A study of differential microRNA expression profile in migraine: The microMIG exploratory study","volume":"24","author":"Gallardo","year":"2023","journal-title":"J. Headache Pain"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Eising, E., A Datson, N., van den Maagdenberg, A.M.J.M., and Ferrari, M.D. (2013). Epigenetic mechanisms in migraine: A promising avenue?. BMC Med., 11.","DOI":"10.1186\/1741-7015-11-26"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s13148-023-01604-8","article-title":"Alterations in DNA methylation associate with reduced migraine and headache days after medication withdrawal treatment in chronic migraine patients: A longitudinal study","volume":"15","author":"Mehta","year":"2023","journal-title":"Clin. Epigenetics"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s10194-019-0989-9","article-title":"CALCA and TRPV1 genes polymorphisms are related to a good outcome in female chronic migraine patients treated with OnabotulinumtoxinA","volume":"20","author":"Ruiz","year":"2019","journal-title":"J. Headache Pain"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/head.13529","article-title":"CGRP and the Trigeminal System in Migraine","volume":"59","author":"Iyengar","year":"2019","journal-title":"Headache"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s10194-022-01498-6","article-title":"Predictors of response to anti-CGRP monoclonal antibodies: A 24-week, multicenter, prospective study on 864 migraine patients","volume":"23","author":"Barbanti","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s10194-023-01698-8","article-title":"What to do with non-responders to CGRP(r) monoclonal antibodies: Switch to another or move to gepants?","volume":"24","author":"Vuralli","year":"2023","journal-title":"J. Headache Pain"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s10194-024-01787-2","article-title":"MicroRNA profiling in women with migraine: Effects of CGRP-targeting treatment","volume":"25","author":"Ornello","year":"2024","journal-title":"J. Headache Pain"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.brainres.2010.12.072","article-title":"Association study of calcitonin gene-related polypeptide-alpha (CALCA) gene polymorphism with migraine","volume":"1378","author":"Menon","year":"2011","journal-title":"Brain Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.gene.2012.11.053","article-title":"Association study of the calcitonin gene-related polypeptide-alpha (CALCA) and the receptor activity modifying 1 (RAMP1) genes with migraine","volume":"515","author":"Sutherland","year":"2013","journal-title":"Gene"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10048-012-0325-x","article-title":"A genome-wide analysis of \u2018Bounty\u2019 descendants implicates several novel variants in migraine susceptibility","volume":"13","author":"Cox","year":"2012","journal-title":"Neurogenetics"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Rubino, E., Boschi, S., Giorgio, E., Pozzi, E., Marcinn\u00f2, A., Gallo, E., Roveta, F., Grassini, A., Brusco, A., and Rainero, I. (2022). Analysis of the DNA methylation pattern of the promoter region of calcitonin gene-related peptide 1 gene in patients with episodic migraine: An exploratory case-control study. Neurobiol. Pain, 11.","DOI":"10.1016\/j.ynpai.2022.100089"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s10194-021-01295-7","article-title":"Role of CGRP pathway polymorphisms in migraine: A systematic review and impact on CGRP mAbs migraine therapy","volume":"22","author":"Scuteri","year":"2021","journal-title":"J. Headache Pain"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Belinskaia, M., Wang, J., Kaza, S.K., Antoniazzi, C., Zurawski, T., Dolly, J.O., and Lawrence, G.W. (2023). Bipartite Activation of Sensory Neurons by a TRPA1 Agonist Allyl Isothiocyanate Is Reflected by Complex Ca(2+) Influx and CGRP Release Patterns: Enhancement by NGF and Inhibition with VAMP and SNAP-25 Cleaving Botulinum Neurotoxins. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021338"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/head.13849","article-title":"Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review","volume":"60","author":"Burstein","year":"2020","journal-title":"Headache"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s10194-024-01925-w","article-title":"Combining treatments for migraine prophylaxis: The state-of-the-art","volume":"25","author":"Pellesi","year":"2024","journal-title":"J. Headache Pain"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s10194-024-01735-0","article-title":"The impact of primary headaches on disability outcomes: A literature review and meta-analysis to inform future iterations of the Global Burden of Disease study","volume":"25","author":"Montisano","year":"2024","journal-title":"J. Headache Pain"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1001\/jamaoncol.2016.4905","article-title":"Predictive Value of FcR Polymorphisms: A Further Step on the Long and Winding Road to Application","volume":"3","author":"Dolcetti","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Fila, M., Sobczuk, A., Pawlowska, E., and Blasiak, J. (2022). Epigenetic Connection of the Calcitonin Gene-Related Peptide and Its Potential in Migraine. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23116151"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5578","DOI":"10.1007\/s12035-023-03428-2","article-title":"Epigenetic Connections of the TRPA1 Ion Channel in Pain Transmission and Neurogenic Inflammation\u2014A Therapeutic Perspective in Migraine?","volume":"60","author":"Fila","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s10194-004-0099-5","article-title":"A one-year retrospective economic evaluation of botulinum toxin type A treatment of chronic tension headache","volume":"5","author":"Mennini","year":"2004","journal-title":"J. Headache Pain"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Corasaniti, M.T., Bagetta, G., Nicotera, P., Tarsitano, A., Tonin, P., Sandrini, G., Lawrence, G.W., and Scuteri, D. (2023). Safety of Onabotulinumtoxin A in Chronic Migraine: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Toxins, 15.","DOI":"10.3390\/toxins15050332"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Ailani, J., McAllister, P., Winner, P.K., Chakhava, G., Krog Josiassen, M., Lindsten, A., Sperling, B., Ettrup, A., and Cady, R. (2022). Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: Results from the randomized RELIEF trial. BMC Neurol., 22.","DOI":"10.1186\/s12883-022-02714-1"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1001\/jama.2021.7665","article-title":"Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial","volume":"325","author":"Winner","year":"2021","journal-title":"JAMA"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Ceccardi, G., Schiano di Cola, F., Caratozzolo, S., Di Pasquale, M., Bolchini, M., Padovani, A., and Rao, R. (2023). Onabotulinumtoxin-A: Previous Prophylactic Treatment Might Improve Subsequent Anti-CGRP Monoclonal Antibodies Response in Patients with Chronic Migraine. Toxins, 15.","DOI":"10.3390\/toxins15120677"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s42399-024-01745-8","article-title":"Is Eptinezumab the Key to Reducing Chronic Migraine Disability?","volume":"6","author":"Shahid","year":"2024","journal-title":"SN Compr. Clin. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/17581869.2025.2487413","article-title":"Efficacy and safety of mAbs anti-CGRP\/CGRP R (eptinezumab and erenumab) or atogepant in combination with onabotulinumtoxinA in refractory chronic migraine: A clinical trial protocol","volume":"15","author":"Scuteri","year":"2025","journal-title":"Pain Manag."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/17\/7\/355\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:11:03Z","timestamp":1760033463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/17\/7\/355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":55,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["toxins17070355"],"URL":"https:\/\/doi.org\/10.3390\/toxins17070355","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]}}}